Precisely Target Underlying Molecular Cause to Curatively Treat HFpEF
The 2nd HFpEF & HCM Drug Discovery & Development Summit unites cardiovascular drug sponsors to target, stratify and curatively treat HFpEF and related cardiomyopathies more precisely.
Understand scientific advances into target identification, leverage strategic cross-stakeholder discussions into their precision medicine approaches, evaluate more cost-effective phase 2 clinical trials, and get up to speed on the wave of cell and gene into precision medicine… in one place, at one unrivalled forum.
Download the full event guide below to see the full 27 expert speakers and pre-competitive conversations driving the next wave of cardiovascular disease management.
Join Your Peers to:
Highlight the importance of genes
Integrate genomics to decision-making practices in HFpEF and HCM treatments by improving left ventricular relaxation with Sardocor and Novartis
Find next-generation technologies
Learn of new metabolic and RNA therapies for identifying new subgroups of the patient population with Novartis, Cardior Pharmaceuticals, and Avidity Biosciences
Pioneer machine learning development
Explore biomarkers for HFpEF clinical trials to obtain more accurate results with Amgen and Novartis
Expand insights for novel therapies
Identify best clinical trial designs and novel measurements to treat disease for genetically defined populations within heart failure and rare cardiomyopathies with Pfizer, Renovacor, and Bristol Myers Squibb
Focus on precision medicine advances
Catapult therapies into successful clinical outcomes by targeting patient populations with common characteristics with Prokidney, and Regeneron
Who will you Meet?
What Your Peers Are Saying:
"Great opportunity for exchange with experts tackling the same challenges in the field, sharing learnings, and making new connections to the benefit of all stakeholders"
Richard Nkulikiyinka,Vice President, Head of Therapeutic Area Cardiology & Nephrology, Bayer
"Sharing our experience with fellow researchers in terms of contemporary knowledge regarding disease drivers of HFpEF as well clinical diagnostic approaches to quantify microvascular dysfunction."
Li-Min Gan, Vice President & Head of Early Clinical Development, AstraZeneca
"Inspiring mix of presentations, engaged speakers, well assembled program, close interaction with supporting team, complementary format adding to other conference series to foster our mission to better help patients with HFpEF."
Lothar Roessig, Vice President & Group Head of Clinical Development, Bayer